Skip to main content

Research Repository

Advanced Search

Vascular endothelial growth factor-A165b is protective and restores endothelial glycocalyx in diabetic nephropathy

Oltean, Sebastian; Qiu, Yan; Ferguson, Joanne K.; Stevens, Megan; Neal, Chris; Russell, Amy; Kaura, Amit; Arkill, Kenton P.; Harris, Kirstie; Symonds, Clare; Lacey, Katja; Wijeyaratne, Lihini; Gammons, Melissa; Wylie, Emma; Hulse, Richard P.; Alsop, Chloe; Cope, George; Damodaran, Gopinath; Betteridge, Kai B.; Ramnath, Raina; Satchell, Simon C.; Foster, Rebecca R.; Ballmer-Hofer, Kurt; Donaldson, Lucy F.; Barratt, Jonathan; Baelde, Hans J.; Harper, Steven J.; Bates, David O.; Salmon, Andrew H.J.

Authors

Sebastian Oltean

Yan Qiu

Joanne K. Ferguson

Megan Stevens

Chris Neal

Amy Russell

Amit Kaura

Kirstie Harris

Clare Symonds

Katja Lacey

Lihini Wijeyaratne

Melissa Gammons

Emma Wylie

Richard P. Hulse

Chloe Alsop

George Cope

Gopinath Damodaran

Kai B. Betteridge

Raina Ramnath

Simon C. Satchell

Rebecca R. Foster

Kurt Ballmer-Hofer

Lucy F. Donaldson

Jonathan Barratt

Hans J. Baelde

Steven J. Harper

DAVID BATES David.Bates@nottingham.ac.uk
Professor of Oncology

Andrew H.J. Salmon



Abstract

Diabetic nephropathy is the leading cause of ESRD in high-income countries and a growing problem across the world. Vascular endothelial growth factor-A (VEGF-A) is thought to be a critical mediator of vascular dysfunction in diabetic nephropathy, yet VEGF-A knockout and overexpression of angiogenic VEGF-A isoforms each worsen diabetic nephropathy. We examined the vasculoprotective effects of the VEGF-A isoform VEGF-A165b in diabetic nephropathy. Renal expression of VEGF-A165b mRNA was upregulated in diabetic individuals with well preserved kidney function, but not in those with progressive disease. Reproducing this VEGF-A165b upregulation in mouse podocytes in vivo prevented functional and histologic abnormalities in diabetic nephropathy. Biweekly systemic injections of recombinant human VEGF-A165b reduced features of diabetic nephropathy when initiated during early or advanced nephropathy in a model of type 1 diabetes and when initiated during early nephropathy in a model of type 2 diabetes. VEGF-A165b normalized glomerular permeability through phosphorylation of VEGF receptor 2 in glomerular endothelial cells, and reversed diabetes-induced damage to the glomerular endothelial glycocalyx. VEGF-A165b also improved the permeability function of isolated diabetic human glomeruli. These results show that VEGF-A165b acts via the endothelium to protect blood vessels and ameliorate diabetic nephropathy.

Journal Article Type Article
Acceptance Date Oct 15, 2014
Publication Date Aug 1, 2015
Deposit Date Aug 28, 2018
Print ISSN 1046-6673
Electronic ISSN 1533-3450
Publisher American Society of Nephrology
Peer Reviewed Peer Reviewed
Volume 26
Issue 8
DOI https://doi.org/10.1681/ASN.2014040350
Public URL https://nottingham-repository.worktribe.com/output/1104781
Publisher URL https://jasn.asnjournals.org/content/26/8/1889
PMID 25542969
Additional Information eStaffProfile Description: , eStaffProfile Brief Description of Type: